Manufacturer of Controlled Substances; Notice of Registration, 34039 [E7-11906]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 9, 2007,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxycodone (9143), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than August 20, 2007.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11903 Filed 6–19–07; 8:45 am]
The company plans to manufacture
the listed controlled substance for sale
to its customer.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than August 20, 2007.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11904 Filed 6–19–07; 8:45 am]
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated February 5, 2007, and
published in the Federal Register on
February 12, 2007, (72 FR 6578),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Schedule
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 4, 2007,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine dimesylate (1205), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the listed controlled substances in bulk
for sales to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
rwilkins on PROD1PC63 with NOTICES
Jkt 211001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2007,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Hydromorphone (9150), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than August 20, 2007.
Manufacturer of Controlled
Substances; Notice of Application
18:25 Jun 19, 2007
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Dextropropoxyphene, bulk (nondosage form) (9273).
Fentanyl (9801) ............................
VerDate Aug<31>2005
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control,Drug Enforcement
Administration.
[FR Doc. E7–11906 Filed 6–19–07; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Application
Drug
Drug Enforcement Administration
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
34039
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
II
II
II
II
II
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Page 34039]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11906]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated February 5, 2007, and published in the Federal
Register on February 12, 2007, (72 FR 6578), Cambrex Charles City,
Inc., 1205 11th Street, Charles City, Iowa 50616, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Phenylacetone (8501)....................... II
Dextropropoxyphene, bulk (non-dosage form) II
(9273).
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sales to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambrex Charles City, Inc. to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has investigated Cambrex Charles City, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control,Drug
Enforcement Administration.
[FR Doc. E7-11906 Filed 6-19-07; 8:45 am]
BILLING CODE 4410-09-P
